Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.03%
0%
14.03%
6 Months
-45.12%
0%
-45.12%
1 Year
305.67%
0%
305.67%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Anbio Biotechnology for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.20%
EBIT Growth (5y)
-9.35%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.17%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
1692
Industry P/E
Price to Book Value
244.02
EV to EBIT
2007.02
EV to EBITDA
2007.02
EV to Capital Employed
770.32
EV to Sales
489.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
38.38%
ROE (Latest)
14.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
Bollinger Bands
Bullish
Moving Averages
Bearish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 1 Schemes (0.04%)
Foreign Institutions
Held by 2 Foreign Institutions (0.11%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
8.90
7.30
21.92%
Operating Profit (PBDIT) excl Other Income
2.20
2.10
4.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.60
2.40
8.33%
Operating Profit Margin (Excl OI)
243.80%
292.20%
-4.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 21.92% vs -70.45% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 8.33% vs -77.14% in Dec 2023






